Richard S. Finn, MD

UCLA professor, Richard S. Finn, MD, discusses the next possible regimen for hepatocellular carcinoma.

Richard S. Finn, MD, discusses key takeaways of the LEAP-002 trial of frontline pembrolizumab and lenvatinib for hepatocellular carcinoma.

Richard S. Finn, MD, discusses the real-world findings from the REFINE study of patients with unresectable hepatocellular carcinoma who received treatment with regorafenib.

Richard S. Finn, MD, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.    

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the role of immunotherapy in the treatment of liver cancer.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.

Richard S. Finn, MD, discusses current research in triple-negative breast cancer

Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.